anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
If significant diarrhea occurs during therapy, lincomycin injection should be discontinued. (see BOXED WARNING) 

INTRAMUSCULAR—Adults: Serious infections—600 mg (2 mL) intramuscularly every 24 hours. More severe infections—600 mg (2 mL) intramuscularly every 12 hours or more often. Pediatric patients over 1 month of age: Serious infections—one intramuscular injection of 10 mg/kg (5 mg/lb) every 24 hours. More severe infections—one intramuscular injection of 10 mg/kg (5 mg/lb) every 12 hours or more often. 

INTRAVENOUS—Adults: The intravenous dose will be determined by the severity of the infection. For serious infections doses of 600 mg of lincomycin (2 mL of lincomycin injection) to 1 gram are given every 8 to 12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given. Intravenous doses are given on the basis of 1 gram of lincomycin diluted in not less than 100 mL of appropriate solution (see PHYSICAL COMPATIBILITIES) and infused over a period of not less than one hour.

These doses may be repeated as often as required to the limit of the maximum recommended daily dose of 8 grams of lincomycin. 

Pediatric patients over 1 month of age: 10 to 20 mg/kg/day (5 to 10 mg/lb/day) depending on the severity of the infection may be infused in divided doses as described above for adults. 

NOTE: Severe cardiopulmonary reactions have occurred when lincomycin injection has been given at greater than the recommended concentration and rate (see PRECAUTIONS). 

SUBCONJUNCTIVAL INJECTION—0.25 mL (75 mg) injected subconjunctivally will result in ocular fluid concentrations of antibacterial (lasting for at least 5 hours) sufficient for most susceptible pathogens.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical agent that is useful for preventing periodontal disease, and to provide an oral cavity composition containing the same.  <P>SOLUTION: The agent for preventing periodontal disease includes, as an active ingredient, a compound having a mucin-type sugar chain-binding site and an integrin recognition site. The mucin-type sugar chain-binding site is derived from a mucin-type sugar chain-binding lectin. The integrin recognition site is derived from a polypeptide having an integrin recognition sequence. The compound is a compound in which the mucin-type sugar chain-binding lectin is bound to the polypeptide having an integrin recognition sequence. There is also provided an oral cavity composition or a toothbrushing tool containing the agent for preventing periodontal disease.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a jelly-like oral medicine composition containing a specific composition as a base agent and capable of being highly easily administered to an aged patient or a deglutition disorder patient. SOLUTION: A base agent containing 0.01-1wt.% of carrageenan, 0.01-1wt.% of locust bean gum, and 0.005-0.05wt.% of polyacrylic acid, its partially neutralized product or its salt is processed into a jelly-like preparation. The jelly-like oral medicine composition is sealed in a disposable container. The disposable container comprises a body portion formed from a synthetic resin, receiving the jelly-like oral medicine composition therein, and capable of being press- deformed, a small diameter circular neck portion connected to the body portion, and a holding portion constituting the closed end of the neck portion communicating with the neck portion in a state capable of being broken off. When the holding portion is broken off from the neck portion, the neck portion is opened to form a pouring opening.  The disposable container enables to easily take a constant volume of the jelly-like oral medicine composition in good throat touch, and is suitable for improving compliance.
Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
It is desired to provide powdery inhalational preparations having little adhesion/aggregation properties in storage and excellent inhalational properties of the active ingredient. Powdery inhalational preparations where in at least the active ingredient adheres to the surface of carrier grains comprising erythritol and/or trehalose. Powdery inhalational preparations wherein at least S-36496 and/or pralmorelin dihydrochloride adhere to the surface of carrier grains. Powdery inhalational preparations wherein at leas t the active ingredient and a surface modifying agent adhere to the surface of  carrier grains. These powdery inhalational preparations are applicable to capsules to be used by using an inhalation device. In addition to the achievement of the above object, powdery inhalational preparations having an  improved taste and relieved unpleasantness in the oral cavity or throat at t he inhalation and a process for conveniently producing the same without resort to any troublesome steps are provided.
Placenta pathology is examined at the time of delivery and can show the underlying pathophysiology of adverse pregnancy outcomes. The Amsterdam consensus has identified four primary categories of injury, acute inflammation, fetal vascular malperfusion, maternal vascular malperfusion, and chronic inflammation associated with adverse obstetric outcomes. Findings from placental pathologic examination performed at delivery can reveal important patterns of injury that lead to adverse pregnancy outcomes but cannot aid in preventing these outcomes. Ultrasound of the placenta may be able to detect placental pathology in the antepartum period to potentially aid in detection and treatment of placental injury. One specific scenario it may be useful in is in the setting of fetal growth restriction, which can be constitutional or pathologic. Identification of growth restriction in the setting of placental injury may identify those patients at greatest risk for adverse outcomes.

In the retrospective portion of this study, researchers will retrospectively evaluate archived ultrasonographic images during pregnancies affected by stillbirth, severe placental histology, fetal growth restriction, and milder histologic abnormalities. The goal of this phase is to develop image processing of placentas and to utilize the image processing of existing sonograms to correlate with the presence or absence of placental pathology at the time of delivery.

The prospective portion of this study the researchers will utilize image processing techniques from the initial phase to prospectively assess placental function. The goal of this phase is to evaluate if placental size, vasculature, and echogenicities among fetuses with suspected growth restriction are associated with maternal vascular mal perfusion on placental pathology. Twenty patients with fetal growth restriction by estimated fetal weight (EFW) \< 10th percentile or fetal abdominal circumference (AC) \< 10th percentile and EFW \< 20th percentile will be recruited as the exposure group. Participants who consent will complete sonographic measurements of the placenta, predefined image capture of color flow to the placenta, and grayscale images every two weeks. Another twenty patients without SGA (small for gestational age) or significant comorbidities will be recruited in the unexposed control group. Upon consenting, these participants will complete sonographic measurements of the placenta for one time. For both groups, information will be abstracted from electronic medical records regarding demographic data, neonatal outcomes, and placental histology. Imaging characteristics will be compared by placental histology and grade of histology at delivery. As this is a pilot project, there is not an a priori power analysis.
This study is an open-label phase I clinical study to evaluate the safety, tolerability , PK/PD and preliminary efficacy of HLX53 in patients with advanced/metastatic solid tumor. 11-30 subjects with advanced or metastatic solid tumors will be enrolled. The accelerated titration and traditional 3 + 3 dose escalation design will be implemented. Subjects will receive intravenous infusion of HLX53 at different doses according to the order of enrollment. There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion. Observation period of DLT will last for 21 days after the first administration of HLX53. Maximum tolerated dose (MTD) definition: The highest dose level at which no more than 1 of 6 DLT-evaluable subjects developed DLT. At the MTD dose, at least 6 subjects were evaluable for DLT. When the MTD is determined, the MTD is usually used as the RP2D, or the RP2D is determined based on safety, PK/PD/ADA/NAb characteristics, and potential clinical efficacy.
The invention provides a preparation method for Chuzhou chrysanthemum extract powder according to the characteristics of effective constituents contained in Chuzhou chrysanthemum, and the preparation method aims at a plurality of effective constituents of the Chuzhou chrysanthemum. A rotary evaporator is adopted to perform double extraction on the Chuzhou chrysanthemum, extracts of volatile oil and acetic acid are obtained, and then decoction dregs are added into ethanol water to perform extraction again with ultrasonic. Beta-cyclodextrin wrapping is performed on the volatile oil to obtain wrappage. Acid extract solution is concentrated, alcohol extract solution is concentrated after alcohol is recovered, two concentrated solutions are merged, and freeze-dried powder is obtained after the two concentrated solutions are frozen and dried. Eventually, the wrappage and the freeze-dried powder are porphyrized and mixed to obtain the Chuzhou chrysanthemum extract powder. According to the preparation method for the Chuzhou chrysanthemum extract powder, the extract method is selected aiming at the characteristics of the plurality of effective constituents of the Chuzhou chrysanthemum, and each effective substance is retained to the maximum extent; extraction time is short, the temperature for the whole process is smaller than or equal to 80 DEG C, damage to efficacy material is avoided, and the preparation method is high in efficiency, time-saving and labor-saving; and the extract powder can be used in place of the Chuzhou chrysanthemum, and can also serve as raw material for production of medicine and health care products.
OBJECTIVES: I. Determine the anticancer efficacy of 506U78 in patients with chronic lymphocytic leukemia refractory to fludarabine and alkylator therapy. II. Determine the safety (including incidence of infection) of this drug in these patients. III. Evaluate the pharmacokinetics of 506U78 and ara-G, and assess the intracellular pharmacokinetics of ara-GTP in patients receiving multiple treatment courses (at M.D. Anderson Cancer Center only). IV. Determine the response rate, time to maximal response, and duration of response in patients treated with this drug. V. Determine two-year survival and progression-free survival of patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to cellular type of disease (B cell vs T cell). Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 28 days and then every 2 months for 2 years until disease progression. After disease progression, patients are followed every 3 months for 2 years.

PROJECTED ACCRUAL: Approximately 14-100 patients will be accrued for this study.
Goltz syndrome is a rare X-linked dominant multisystem disorder that presents with ectoderm and mesoderm-derived symptoms. Skin manifestations including congenital patchy skin aplasia, congenital nodular fat herniation, congenital hypo- or hyperpigmentation along Blaschko's lines, telangiectasia, and congenital ridged dysplastic nails are typical in this disorder. Almost all cases of Goltz syndrome correspond to female newborns and that hemizygosis makes the syndrome fetal in males. Triple X syndrome is a relatively common congenital disorder that presents with mild to no symptoms in the developmental and psychiatric realm. The patient reported here was born with multisystem anomaly affecting the eyes, craniofacial region, cardiovascular system, skin, and limbs. A G-banding chromosomal study revealed 47, XXX. She was diagnosed with Goltz syndrome owing to her distinctive skin manifestations. The congenital cervical skin defect healed with conservative treatment. The facial cleft, cleft lip-palate, and syndactyly were successfully treated with multiple surgical treatments. The combination of triple X syndrome and Goltz syndrome is very rare. We describe the expression of presenting with both syndromes simultaneously.
<P>PROBLEM TO BE SOLVED: To provide a method for the treatment of mammalian retrovirus infections (e.g. HIV), using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo.  <P>SOLUTION: The invention, in particular, relates to protease inhibitor compounds used in combination therapy with other protease inhibitor compounds. The invention also relates to combination therapy with a combination of protease inhibitors and antiviral agents other than protease inhibitors. The new resin composition utilizing a lignophenol derivative is also provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
FIELD: pharmacy. SUBSTANCE: pharmaceutical form consists of drug in combination with matrix that consists of saccharide-containing polymer. Form is resistant to enzymatic cleavage in patient stomach and intestine to whom this delivery system is administrated in colon. Pharmaceutical drug form is delivered in colon by enteral method of administration of biologically active compound at effective drug doses used at colon damage treatment. Invention describes a method of preparing sugar-containing polymers containing oligosaccharides and useful as a matrix for delivery system of drugs in colon. Invention proposes methods of modification of natural polymers such as mucopolysaccharides and, especially, chondroitin and pectin that can be used as matrix for pharmaceutical form of drugs according to the invention proposed. EFFECT: improved method of preparing and administration of drug. 47 cl, 11 dwg , 1 tbl
It has been found that placenta alkaline phosphatase interacts synergistically with growth factors and corresponding serum factors to stimulate the proliferation of adult fibroblast cells. Furthermore, this stimulation of fibroblast proliferation does not result in a corresponding stimulation of collagen synthesis. Thus, wound healing compositions can be formulated that improve wound healing without increasing scar formation. Compositions for wound healing can include placental alkaline phosphatase and a gel-forming material. In some embodiments, compositions include placental alkaline phosphatase and serum/growth factors. In addition to wound healing applications, compositions with placental alkaline phosphatase can also be used in cell sulturing of adult fibroblast cells.
This study represents a hybrid design type 3 focusing primarily on implementation outcomes and secondarily on clinical effectiveness among trans women living with HIV receiving care within primary care clinics in San Francisco. A type 3 design was chosen, as the clinical efficacy of CAB- RPV LA has been established in clinical trials, and the focus of this study is on initial implementation of CAB-RPV LA within these clinics.
PURPOSE: A pill formulation containing herbs is provided to treat and prevent urinary incontinence and to reduce disgusting smell. CONSTITUTION: A method for manufacturing a pill formulation for preventing and treating urinary incontinence comprises: a step of drying and pulverizing Plygonum cuspidatum Sieb. et Zucc. root to prepare Plygonum cuspidatum Sieb. et Zucc. root powder; a step of drying and pulverizing Artemisia capillaris Thumb.; a step of mixing Plygonum cuspidatum Sieb. et Zucc. root powder and Artemisia capillaris Thumb. powder; a step of mixing with water and heating at 150-250 degrees Celsius for 15 hours to prepare Plygonum cuspidatum Sieb. et Zucc. root gel and Artemisia capillaris Thumb. gel; and a step of drying in a pill.
Participants in this condition will receive daily step goals calculated as the 60th percentile of their last 9 days of available daily steps data. Goals will be transmitted over text message, and will be accompanied by information about the participant's steps on the previous day and whether they met their goal the previous day.
NEW MATERIAL:A compound expressed by formula I (Q is 1-8C alkyl, biphenyl or heterocycle substitutable with halogen, lower alkyl, nitro, carbamoyl or phenyl, etc.), a salt or a solvate of said compound and a solvate of said salt. EXAMPLE:1-(Benzo[b]thien-2-yl sulfonyl) hydantoin. USE:Useful for therapy and prevention of various complications of diabetes, having aldose reductase-inhibiting action and simultaneously exhibiting cataract- inhibiting action, nervous incompetency inhibiting action and hypoglycemic action. PREPARATION:A sulfonylglycine derivative expressed by formula II is cyclized with halogenated formic acid ester in a solvent such as N,N-dimethylformamide in the presence of a base (e.g., NaH) at a temp. from -20 deg.C to 120 deg.C to afford the compound expressed by formula I.
Toothpaste for preventing dental caries, loosening of the teeth and the like contains fillers and/or abrasives and at least one F cpd. and optionally water-absorbent, wetting and thickening agents, antibacterials and flavours. The F-compds. have formula XMnFy where X = alkali (ne earth) metal, Mn is bivalent and y = z + 2, being the valency of X. The fillers or abrasives consist of small particles plastics e.g. polymethylmethacrylate, or of Ca3(PO4)2 or SiO2 coated with such plastics. A reduced quantity of F-compd. can protect the enamel without endangering the gums as only little is absorbed on the fillers or abrasives.
The present invention provides a morphinan derivative having a nitrogen-containing cyclic structure of formula (I) or its pharmacologically acceptable acid addition salts: [Wherein R1 represents a methyl, cyclopropylmethyl etc.; R2 and R3 represents hydroxy, methoxy, acetoxy etc.; Y and Z together represents a bond or -C(=O)- etc.; X represents a C2-5 carbon chain forming a part of the cyclic structure (wherein one of carbons is optionally substituted by an oxygen, sulfur or nitrogen atom) etc.; (R4)k represents a condensed benzene ring, carbonyl etc.; R9 represents a hydrogen etc.; R10 and R11 are combined to form -O- etc.; and R6 represents a hydrogen etc.]; a therapeutic or prophylactic agent of frequent urination and urinary incontinence containing said morphinan derivative or its pharmacologically acceptable acid addition salts as the effective constituent; a method of treatment or prophylaxis of frequent urination and urinary incontinence; and the use of said morphinan derivative in said disorders. The compound according to the present invention is useful as a novel therapeutic or prophylactic agent of frequent urination and urinary incontinence with little side effects, as well as can be used in the method of treatment or prophylaxis of said disorders and has the use in said disorders.
A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung, or hyperinflated lung syndrome, and instilling a minimum effective dose of a perfluorochemical liquid or emulsion through the trachea for coating the alveolar sacs of a lung of the mammal. The preferred perfluorochemicals have a very low vapor pressure to avoid inducing hyperinflated lung syndrome and are supplied in a minimum effective dosage sufficient to coat the inner lung surfaces. The perfluorochemicals are permeable to the ambient gas and reside substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O2/CO2 blood gas exchange. Effective coating of the lungs with a small (generally <0.1 ml/kg) dose of very low vapor pressure perfluorochemical is achieved through administration of an aqueous emulsion of the perfluorochemical or a mixture of the very low vapor pressure compound in a larger volume of a higher vapor pressure carrier perfluorochemical.
The active ingredient in gabapentin capsules, and tablets is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid.

The molecular formula of gabapentin is C9H17NO2 and the molecular weight is 171.24. The structural formula of gabapentin is:

Gabapentin is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.25.

Each gabapentin capsule, USP contains 100 mg, 300 mg, or 400 mg of gabapentin, USP and the following inactive ingredients: calcium carbonate, calcium sulfate dihydrate, glyceryl behenate, and pregelatinized maize starch. The capsule shell contains gelatin, titanium dioxide, sodium lauryl sulfate, yellow iron oxide (300 mg and 400 mg) and red iron oxide (400 mg). The imprinting ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide, potassium hydroxide, and purified water.

Each gabapentin tablet contains 600 mg or 800 mg of gabapentin, USP and the following inactive ingredients: glyceryl behenate, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, talc, pregelatinized maize starch and Opadry YS-1-7003 (hypromellose, titanium dioxide, polyethylene glycol, and polysorbate 80).